Royalty Pharma (RPRX) Q1 FY26 earnings call

Royalty Pharma delivered a strong Q1 FY26 with double-digit growth in both portfolio and royalty receipts, driven by its diversified portfolio and strategic capital allocation. The company made significant investments in new royalties and R&D co-funding agreements, while also strengthening its global platform and leadership team. Full-year guidance was raised, reflecting confidence in continued momentum despite some headwinds from LOE and lower milestone receipts.